Literature DB >> 27003515

A triad of telomerase, androgen receptor and early growth response 1 in prostate cancer cells.

Sheeba Jacob1, Sumeet Nayak1, Ruchi Kakar1, Uddhav K Chaudhari1, Dolly Joshi2, Babu R Vundinti2, Gwendolyn Fernandes3, Ram S Barai4, Sanjeeva D Kholkute1, Geetanjali Sachdeva1.   

Abstract

Telomerase activation is one of the key mechanisms that allow cells to bypass replicative senescence. Telomerase activity is primarily regulated at the level of transcription of its catalytic unit- hTERT. Prostate cancer (PCa), akin to other cancers, is characterized by high telomerase activity. Existing data suggest that hTERT expression and telomerase activity are positively regulated by androgenic stimuli in androgen-dependent prostate cancer (ADPC) cells. A part of the present study reaffirmed this by demonstrating a decline in the hTERT expression and telomerase activity on "loss of AR" in ADPC cells. The study further addressed 2 unresolved queries, i) whether AR-mediated signaling is of any relevance to hTERT expression in castration-resistant prostate cancer (CRPC) and ii) whether this signaling involves EGR1. Our data suggest that AR-mediated signaling negatively regulates hTERT expression in CRPC cells. Incidental support for the possibility of EGR1 being a regulator of hTERT expression in PCa was provided by i) immunolocalization of hTERT and EGR1 proteins in the same cell type (secretory epithelium) of PCa and BPH tissues; ii) significantly (p< 0.001) higher levels of both these proteins in CRPC (PC3 and DU145), compared with ADPC (LNCaP) cells. A direct evidence for the role of EGR1 in hTERT expression was evident by a significant (p<0.0001) decrease in the hTERT transcript levels in the EGR1-silenced CRPC cells. Further, "gain of AR" led to a significant reduction in the levels of hTERT and EGR1 in CRPC cells. However, restoration of EGR1 levels prevented the decline in the hTERT transcript levels in these cells. Taken together, our data indicate that AR regulates the expression of EGR1, which in turn acts as a positive regulator of hTERT expression in CRPC cells. Thus, AR exerts an inhibitory effect on hTERT expression and telomerase activity by modulating EGR1 levels in CRPC cells.

Entities:  

Keywords:  Androgen receptor; EGR-1; hTERT; prostate cancer; telomerase

Mesh:

Substances:

Year:  2016        PMID: 27003515      PMCID: PMC4910915          DOI: 10.1080/15384047.2016.1156255

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

1.  Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.

Authors:  Kenneth A Iczkowski; Cooley G Pantazis; Douglas H McGregor; Yaping Wu; Ossama W Tawfik
Journal:  Cancer       Date:  2002-12-15       Impact factor: 6.860

2.  Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.

Authors:  Mitsuhiro Suenaga; Hiroshi Soda; Mikio Oka; Akihiko Yamaguchi; Katsumi Nakatomi; Ken Shiozawa; Shigeru Kawabata; Takashi Kasai; Yasuaki Yamada; Shimeru Kamihira; Chuwa Tei; Shigeru Kohno
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

3.  Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.

Authors:  Sheeba Jacob; S Nayak; Gwendolyn Fernandes; R S Barai; S Menon; U K Chaudhari; S D Kholkute; Geetanjali Sachdeva
Journal:  Endocr Relat Cancer       Date:  2014-05-08       Impact factor: 5.678

4.  Regulation of synapsin I gene expression by the zinc finger transcription factor zif268/egr-1.

Authors:  G Thiel; S Schoch; D Petersohn
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

5.  In vivo regulation of hTERT expression and telomerase activity by androgen.

Authors:  Chuanhai Guo; Blaine N Armbruster; David T Price; Christopher M Counter
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

6.  Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers.

Authors:  Bin Xu; Gusheng Tang; Chengwu Xiao; Linhui Wang; Qing Yang; Yinghao Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

7.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

Review 8.  Advances in androgen receptor targeted therapy for prostate cancer.

Authors:  Alia Ahmed; Shadan Ali; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

Review 9.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

Review 10.  Human telomerase activity regulation.

Authors:  Aneta Wojtyla; Marta Gladych; Blazej Rubis
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

View more
  7 in total

1.  Effect of Achillea wilhelmsii extract on expression of the human telomerase reverse transcriptase mRNA in the PC3 prostate cancer cell line.

Authors:  Mojtaba Ashtiani; Fariba Nabatchian; Hamid Reza Galavi; Ramin Saravani; Farzaneh Farajian-Mashhadi; Saeedeh Salimi
Journal:  Biomed Rep       Date:  2017-07-31

2.  MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.

Authors:  Atrayee Bhattacharya; Atsushi Fushimi; Nami Yamashita; Masayuki Hagiwara; Yoshihiro Morimoto; Hasan Rajabi; Mark D Long; Maha Abdulla; Rehan Ahmad; Kelly Street; Song Liu; Tao Liu; Donald Kufe
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 5.852

Review 3.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096

Review 4.  Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer.

Authors:  Mohammad Taheri; Soudeh Ghafouri-Fard; Sajad Najafi; Julia Kallenbach; Elmira Keramatfar; Golnaz Atri Roozbahani; Mehdi Heidari Horestani; Bashdar Mahmud Hussen; Aria Baniahmad
Journal:  Cancer Cell Int       Date:  2022-08-16       Impact factor: 6.429

5.  TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.

Authors:  Lucy Cassar; Craig Nicholls; Alex R Pinto; Ruping Chen; Lihui Wang; He Li; Jun-Ping Liu
Journal:  Protein Cell       Date:  2016-09-30       Impact factor: 14.870

6.  Egr-1 mediates leptin-induced PPARγ reduction and proliferation of pulmonary artery smooth muscle cells.

Authors:  Xinming Xie; Shaojun Li; Yanting Zhu; Lu Liu; Rui Ke; Jian Wang; Xin Yan; Lan Yang; Li Gao; Weijin Zang; Manxiang Li
Journal:  Mol Biol Cell       Date:  2017-12-06       Impact factor: 4.138

Review 7.  Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.

Authors:  Jin Wook Kim
Journal:  Investig Clin Urol       Date:  2020-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.